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Rituximab levels are associated with the B cell 
homeostasis but not with the clinical response in 
patients with rheumatoid arthritis
Introduction 
Advances in knowledge of rheumatoid arthritis (RA) have shown that this disease is not a syndrome 
as different subsets of patients have different prognoses and responses to treatment. Our greater 
understanding of the pathogenesis of the disease has also led to the development of biological 
therapies. One such therapy is rituximab (RTX), a glycosylated chimeric mouse/human monoclonal 
antibody directed toward CD20, a pan‐B surface marker that depletes B lymphocytes. B cell deple-
tion after RTX treatment differs in distinct diseases, tissues, and from patient to patient (1‐2). As in 
other diseases, such as lymphoma (3), and with other biological therapies (4), higher serum levels of 
RTX should predict a better B cell depletion and clinical response. However, to date, studies of RTX 
levels in patients with RA have not found an association between RTX levels and clinical outcomes. 
None of these studies completed the B cell count or determined RTX levels beyond 3 months. We 
prospectively analyzed clinical outcomes and B cell and RTX levels in an RA cohort during a com-
plete course of treatment. 
Methods
Peripheral blood samples were obtained from 34 patients who met the American College of Rheuma-
tology criteria for RA. Treatment with RTX was started following standard clinical practice. All patients 
were refractory to treatment with synthetic disease‐modifying antirheumatic drugs, including metho-
trexate, and tumor necrosis factor antagonists. The study was approved by the ethics committee of the 
Hospital de Sant Pau according to the Declaration of Helsinki. Written consent was obtained from all 
patients. Heparinized blood samples were collected on days 0 (baseline, before treatment), 30, 90, and 
180 days after the first RTX infusion. Every course cycle consisted of two doses of RTX (1000 mg) 2 weeks 
apart. Nine patients had minor infusion reactions that required a slower infusion rate, but completed 
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Objective: To study the levels of rituximab (RTX) and anti-RTX antibodies (ARAs) in patients with rheu-
matoid arthritis (RA) at 30, 90, and 180 days after the first infusion, in relation to clinical and serological 
parameters and B cell homeostasis. 
Methods: Thirty-four patients with RA who failed to respond to anti-tumor necrosis factor therapy 
received RTX. At baseline, 4, 12, and 24 weeks after the first infusion of RTX, we performed a clinical 
assessment and determined the levels of RTX, ARAs, B cells, rheumatoid factors, anti-cyclic citrullinat-
ed peptide antibodies, immunoglobulins, and complements. 
Results: RTX levels varied widely among patients. No ARAs were detected during the follow-up. Pa-
tients with lower levels of RTX presented with higher decreases in erythrocyte sedimentation rate, 
immunoglobulins, and complement 6 months after the first infusion. Patients with higher levels of 
RTX showed a higher B cell depletion at 90 days but an earlier B cell recovery than those with lower 
levels of RTX. No differences in clinical response were observed between the two groups at 6 months 
after starting the treatment. 
Conclusion: Our findings suggest that RTX levels in the serum of patients with RA are related to B 
cell homeostasis and the severity of immunological parameters but not to the clinical response at 6 
months.
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treatment. One patient presented a major 
infusion. Treatment was terminated, and the 
patient was excluded. At all visits, we deter-
mined erythrocyte sedimentation rate (ESR), 
C‐reactive protein (CRP), immunoglobulins 
(IgG, IgA, and IgM), complements (C3 and C4), 
rheumatoid factor (RF), anti‐cyclic citrullinat-
ed peptide antibodies (ACPAs), and RTX and 
anti‐RTX levels. 
Flow cytometry 
Venous blood was processed for flow cytom-
etry as described previously, within 2 h of col-
lection (5). Monoclonal antibodies used were 
as follows: Cyto‐STAT tetrachrome system 
lymphocyte cocktail (anti‐CD45‐FITC/CD4‐
phycoerythrin (PE)/CD8‐PE‐Texas red (ECD)/
CD3‐PE‐Cy5) and Natural Killer (NK) cocktail 
(anti‐CD45‐FITC/CD19‐ECD/CD3‐PE‐Cy5/
CD56‐PE) (Beckman Coulter). Analysis was 
performed on a Cytomics FC 500 using CXP 
software (Beckman Coulter). Sphero Rainbow 
Calibration particles (Spherotech, Lake Forest, 
IL, USA) were used for periodic calibration of 
channels.
RTX and anti-RTX levels in serum 
Sera were tested for RTX (PG‐M‐127‐01‐
PROMONITOR®‐RTX) and anti‐RTX levels 
PG‐M‐127‐02‐PROMONITOR®‐RTX) using spe-
cific ELISAs according to the manufacturer’s 
instructions. 
Statistical Analysis 
Calculations were performed using Statis-
tical Packages of Social Sciences version 18 
(SPSS Inc.; Chicago, IL, USA). Results were 
expressed as mean±SEM. Mann–Whitney U 
test and Wilcoxon’s test were used for inde-
pendent and related variables respectively, 
at different time‐points during the follow-up. 
A p‐value of ≤0.05 was considered statistical-
ly significant. 
Results
A total of 34 patients were included in the 
study. The mean age of the patients was 62.4 
(37–81) years, and 93.1% were women. Dis-
ease duration was 15.7 (10.7) years. Only 9.09% 
were RF and ACPA negative. Of the 34 patients, 
55.6% were on monotherapy, and 33.3% were 
on methotrexate. 
RTX and anti-RTX levels 
As shown in Figure 1, the peak of RTX lev-
els was observed 30 days after initiating 
treatment. As in previous studies (6‐9), 
RTX levels were highly variable and ranged 
from 13,000 pg/mL to 115,000 pg/mL. After 
treatment for 90 days, RTX levels decreased 
significantly but were detectable in 80% of 
patients. No RTX was detected on day 180. 
As in other studies, no anti‐RTX antibodies 
(ARAs) were detected during the follow-up 
(9). 
Effects of RTX levels on clinical and laboratory pa-
rameters and B cell recovery 
To analyze the association between RTX 
levels and clinical and immunological pa-
rameters, patients were segregated into 
two groups according to RTX levels at 30 
days. Patients with RTX levels >56,000 pg/
mL (group H: 51.5% of patients) and those 
with RTX levels <56,000 pg/mL (group 
L: 48.5% of patients). Patients from both 
groups were comparable before treatment. 
As shown in Table 1, decreases in DAS28, 
CRP, and RF were similar in both groups at 
180 days. However, group L patients pre-
sented a larger decrease of ESR, IgG, IgA, 
IgM, C3, and C4. 
As shown in Figure 2, depletion kinetics and 
recovery of B cells were different in the two 
groups of patients. Patients from group H 
showed a greater initial B cell depletion than 
those from group L. This greater depletion 
was maintained up to day 90. B cell recovery 
was significantly faster in group H patients. By 
day 180, B cells were still depleted in group L 
(20% of group H patients and 44% of group 
L patients presented <1 CD19+ cell/mL) 
(p=0.028). 
Table 1. Decrements of clinical and analytical values at 180 days after the first rituximab infusion
 Group A Group B 
 (>56,000 pg/mL) (<56,000 pg/mL) p
▼180 DAS28 1.7±1.3 1.7±1 0.96
▼180 ESR (mm/h)   
▼180 ESR (mm/h) 9.1±9.1 37.1±8 0.038
▼180 IgG (mg/dL) 3±3.6 23.3±6.9 0.018
▼180 IgA (mg/dL) 0.8±16.3 16.3±22.6 0.092
▼180 IgM (mg/dL) 24.2±4.5 39.2±4.2 0.03
▼180 RF (UI/mL) 56.7±6.4 53.3±10.9 0.7
▼180 C3 (mg/dL) −13±4.7 6±3.7 0.005
▼180 C4 (mg/dL) −20±4.6 −3.7±7.8 0.07
B cells on day 180 (cells/mL) 9.7±3.2 1.3±0.4 0.03
Figure 1. Rituximab levels evolution from baseline to 180 days after RTX first infusion. RTX levels 
were highly variable from 13,000 to 115,000 pg/mL. After the first infusion for 90 days, RTX levels 
were still detectable in 80% of patients
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Discussion 
We found that higher decreases of immuno-
logical parameters were associated with low-
er levels of RTX. In addition, the recovery of B 
cells was delayed in patients with lower levels 
of RTX. This finding appears to contradict pre-
vious studies in patients with lymphoma or lu-
pus treated with RTX that higher levels of RTX 
in sera were associated with better outcomes 
and a stronger B cell depletion (3). Differenc-
es in RTX levels and in B cell recovery pace 
between patients with RA and lymphoma are 
not surprising because doses of the drug and 
B cell distribution differ significantly in these 
two diseases. In RA, most active B lymphocytes 
are found in the germinal centers of the lymph 
nodes, bone marrow, spleen, or other similar 
structures, such as lymphocyte aggregates in 
the synovium. These were probably memory B 
cells searching for an environment that favors 
their stimulation and survival (10). 
In other biological therapies, higher drug con-
centrations in the peripheral blood of patients 
with RA were related to better outcomes (4). 
However, few groups have studied the RTX 
levels and the association with clinical or ra-
diological response and B cell depletion in pa-
tients with RA. One previous study, with results 
similar to our own, reported a great variability in 
serum levels and the highest value on day 30. 
The authors found that patients with ARAs had 
lower RTX levels. However, they did not find any 
association between RTX levels and clinical out-
come, radiological progression, or synovial B cell 
depletion at 12 or 16 weeks (8). Another study 
observed, as we did, that higher RTX levels were 
associated with higher peripheral B lymphocyte 
depletion levels on days 30 and 90 after the 
first infusion (7). Unfortunately, the authors did 
not show results further than 90 days, the time 
when we observed that peripheral B cell recov-
ery began in patients with higher levels of RTX. 
There are several explanations for highly vari-
able levels of RTX in patients with RA: (1) differ-
ences in RTX metabolism, (2) polymorphisms 
in Fc neonatal receptor, a molecule involved in 
the recycling of IgG1 (11), and (3) differences 
in RTX distribution in the body compartments. 
The complex distribution of RTX in different 
body compartments could also explain dif-
ferences among diseases. Positron emission 
tomography/computed tomography imaging 
has shown that immediately after the infusion, 
RTX is located in the spleen and, in a smaller 
quantity, in the bone marrow. After infusion for 
24 h, RTX is mostly located in the thyroid gland. 
It then spreads through the body in a variable 
manner (12‐13). These findings could explain 
the total depletion of B cells in the spleen, but 
not in other compartments, in patients with 
non‐Hodgkin lymphoma (14). 
Based on these data, we speculate that RTX is 
predominantly distributed in the extravascular 
compartments in group L patients, consistent 
with lower RTX levels in the blood. These pa-
tients could have a poorer initial B cell deple-
tion in the blood but a better B cell depletion 
in the germinal centers. Therefore, they could 
have a higher decrease in immunoglobulins in 
the peripheral blood. In addition, poorer initial 
depletion of B cells could induce lower levels 
of B cell activating factor (15), thus delaying B 
cell recovery in group L patients. 
This hypothesis could also explain why the 
treatment response in patients with RA with 
higher levels of RTX in sera was comparable 
with those with lower levels of RTX. It also 
could suggest that patients with lower RTX 
levels could be candidates of RTX treatment 
on demand instead of every 6 months. More 
studies should be conducted to clarify this 
issue.
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